Partial restoration of gut‐mucosal dysbiosis in late‐treated HIV‐infected subjects with CD4 T‐cell recovery

• Published in: Clinical and translational medicine Vol. 12; no. 4; pp. e788 - n/a
• Main Authors: Olivas‐Martínez, Israel, Rosado‐Sánchez, Isaac, Cordero‐Varela, Juan Antonio, Sobrino, Salvador, Genebat, Miguel, Herrero‐Fernández, Inés, Pablos, Rocío Martínez, Carvajal, Ana Eloísa, Ruiz, Rocío, Isabel Álvarez‐Ríos, Ana, Fontillón‐Alberdi, María, Bulnes‐Ramos, Ángel, Garrido‐Rodríguez, Vanesa, Pozo‐Balado, María del Mar, Leal, Manuel, Pacheco, Yolanda María
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2022; John Wiley and Sons Inc; Wiley
• Subjects: Antiretroviral Therapy, Highly Active; Biopsy; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Conflicts of interest; Dysbiosis; HIV; HIV Infections - complications; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Inflammation; Letter to Editor; Microbiota; Small intestine; Taxonomy
• ISSN: 2001-1326; 2001-1326
• DOI: 10.1002/ctm2.788

[...]we aimed to explore potential differences in specific dysbiosis in the gut-mucosal microbiome, comparing biopsies from two different locations (ileum and caecum), of HIV-infected subjects with different clinical phenotypes. SEE PDF] Sequencing data of 16S rRNA from the microbiota present in terminal ileum and caecum samples of study subjects were analysed and compared with bacterial taxonomic databases. [...]parameters of richness and alpha-diversity of the gut microbiome showed no statistically significant differences between healthy and HIV-groups (elite controller [EC], early-treated [ET], late-treated high recovery [LT-HR] and late-treated low recovery [LT-LR]) regardless the biopsied intestinal area (Figure 2A) or patient sex (Figure S1). [...]abundance analyses were performed without separating by gut location. [...]this is the first report to analyse the potential association of the clinical phenotype of HIV-subjects, regarding their CD4 status at cART onset and afterwards, with alterations in the microbiome composition.